EUPRAXIA PHARMACEUTICALS INC (EPRX) Forecast, Price Target & Analyst Ratings

NASDAQ:EPRX • CA29842P1053

Current stock price

7.25 USD
+0.19 (+2.69%)
At close:
7.59 USD
+0.34 (+4.69%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EUPRAXIA PHARMACEUTICALS INC (EPRX).

Forecast Snapshot

Consensus Price Target

Price Target
$11.76
+ 62.18% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.22
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.45%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$11.76
Upside
+ 62.18%
From current price of $7.25 to mean target of $11.76, Based on 11 analyst forecasts
Low
$10.28
Median
$11.66
High
$13.74

Price Target Revisions

1 Month
8.62%
3 Months
8.67%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for EPRX. The average price target is 11.76 USD. This implies a price increase of 62.18% is expected in the next year compared to the current price of 7.25.
The average price target has been revised upward by 8.67% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

EPRX Current Analyst RatingEPRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

EPRX Historical Analyst RatingsEPRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.45%
EPRX was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about EPRX.
In the previous month the buy percentage consensus was at a similar level.
EPRX was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-22HC Wainwright & Co.Reiterate Buy -> Buy
2026-03-23William BlairInitiate Outperform
2026-03-17HC Wainwright & Co.Maintains Buy -> Buy
2026-01-15Cantor FitzgeraldMaintains Overweight -> Overweight
2026-01-09HC Wainwright & Co.Reiterate Buy -> Buy
2025-08-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-07-24Cantor FitzgeraldInitiate Overweight
2025-06-26HC Wainwright & Co.Initiate Buy
2024-11-14Rodman & RenshawInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.22
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-6.98%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
19.68%
EPS (3 Months)
-4.76%

Next Earnings Summary

EPRX is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.22 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
EPRX revenue by date.EPRX revenue by date.
N/AN/AN/AN/AN/A
311.38%		N/A
81.67%		N/A
52.55%		N/A
37.56%
EBITDA
YoY % growth
EPRX ebitda by date.EPRX ebitda by date.
-4.64M-11.75M
-153.23%		-5.99M
49.02%		-2.27M
62.10%		-18.12M
-698.24%		-22.77M
-25.66%		-27.33M
-20.03%		-25.32M
7.36%		-36.598M
-44.54%		N/A
10.29%		N/A
-1.68%		N/A
13.24%		N/A
124.33%		N/A
947.54%		N/A
89.98%		N/A
61.82%		N/A
38.68%
EBIT
YoY % growth
EPRX ebit by date.EPRX ebit by date.
-4.73M-11.88M
-151.16%		-6.19M
47.90%		-2.39M
61.39%		-18.23M
-662.76%		-22.96M
-25.95%		-27.443M
-19.53%		-25.434M
7.32%		-36.836M
-44.83%		N/A
-55.59%		N/A
56.47%		N/A
-231.61%		N/A
48.85%		N/A
237.87%		N/A
162.31%		N/A
70.78%		N/A
44.90%
Operating Margin
EPRX operating margin by date.EPRX operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
EPRX eps by date.EPRX eps by date.
N/AN/AN/AN/AN/AN/A
51.23%		-0.90
-0.93%		-0.75
16.95%		-1.03
-37.27%		N/A
27.73%		N/A
-6.39%		N/A
-20.39%		N/A
38.61%		N/A
196.81%		N/A
186.41%		N/A
77.05%		N/A
24.42%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.22
-6.98%		-0.21
17.61%		-0.22
-15.25%		-0.20
44.90%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-11.864M
-76.73%		-12.298M
-55.46%		-12.527M
-92.19%		-12.757M
18.72%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
2.42%
EPS Next 5 Year
20.59%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
10.00%
EBIT Next 5 Year
29.94%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

EUPRAXIA PHARMACEUTICALS INC / EPRX Forecast FAQ

Can you provide the average price target for EUPRAXIA PHARMACEUTICALS INC stock?

11 analysts have analysed EPRX and the average price target is 11.76 USD. This implies a price increase of 62.18% is expected in the next year compared to the current price of 7.25.

What is the next earnings date for EPRX stock?

EUPRAXIA PHARMACEUTICALS INC (EPRX) will report earnings on 2026-05-07.

What are the consensus estimates for EPRX stock next earnings?

The consensus EPS estimate for the next earnings of EUPRAXIA PHARMACEUTICALS INC (EPRX) is -0.22 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

The consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.